Interleukin-6 as a biomarker of hypersensitivity reactions in chemotherapeutics and monoclonal antibodies.
Rosalaura V Villarreal GonzálezSandra Nora González-DíazOscar Vidal-GutiérrezCarlos de la Cruz-de la CruzDiana C Pérez-IbaveMaría L Garza-RodríguezPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
With the increasing prevalence of hypersensitivity reactions to biologic and antineoplastic therapies, interleukin-6 should be recognized as a biomarker in immediate hypersensitivity reactions to QT and monoclonal antibodies.